Amatuximab
- Generic Name
- Amatuximab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 931402-35-6
- Unique Ingredient Identifier
- 6HP0354G04
- Background
Amatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Amatuximab for High Mesothelin Cancers
Early Phase 1
Terminated
- Conditions
- Carcinoma, Pancreatic DuctalMesotheliomaOvarian NeoplasmsCarcinoma, Non-Small-Cell Lung
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 7
- Registration Number
- NCT01413451
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath